Do you want to read an article? Please log in or register.
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
doi: 10.1007/s00262-018-2239-4.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J Clin Oncol.
Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J
doi: 10.1200/JCO.2018.78.3118.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
★ 0
Recommended and commented by
Prof. Dr Stephan Bodis, Faculty Member
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
doi: 10.1016/S1470-2045(20)30111-X.
Lung, Respiratory and Thoracic CancerSkin Cancer
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Lancet Oncol.
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hedge U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrisch H, Yao X, Chiang V, Kluger HM
doi: 10.1016/
SPECIAL REPORT
Multiple Myeloma (MM)
Traitement du myélome multiple récidivant/réfractaire
Central Nervous System Tumors
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Lancet Oncol
Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA
doi: 10.1016/S1470-2045(21)00545-3
Lung, Respiratory and Thoracic Cancer
Osimertinib for patients with leptomeningeal metastases associated with epidermal growth factor receptor T790M positive advanced NSCLC: the AURA LM analysis
J Thorac Oncol.
Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Yates JWT, Brown AP, Mendoza-Naranjo A, Mok T
doi: 10.1016/j.jtho.2019.12.113.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Eur J Cancer
Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Aerts JGJV, Baldessari C, Giusti R, Ferrara MG, D'Argento E, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Antonuzzo L, Mazzoni F, De Toma A, Signorelli D, Gelibter A, Targato G, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Filetti M, Bracarda S, Citarella F, Marco R, Cantini L, Nigro O, Buti S, Minuti G, Landi L, Ricciardi S, Migliorino MR, Natalizio S, Simona C, De Filippis M, Metro G, Adamo V, Russo A, Spinelli GP, Di Maio M, Banna GL, Friedlaender A, Addeo A, Pinato DJ, Ficorella C, Porzio G
doi: 10.1016/j.ejca.2021.02.005
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group
Lancet Oncol.
Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D1, Soffietti R1, van den Bent MJ, Wefel JS, Wen PY
doi: 10.1016/